“APAC, post-COVID-19, will see an explosion of innovation in digital health”
BioSpectrum Asia|August 2020
The ongoing COVID-19 pandemic plaguing countries worldwide has created unprecedented change for the global economy, especially healthcare institutions at the forefront. Hospitals across the world are facing never before seen challenges that have accelerated the development of technological innovations. As we navigate the complexities of the virus and the amount of disruption it has brought about, one thing is certain – COVID-19 will be with us for the foreseeable future. It’s time to focus on this new reality and how we can achieve a sense of normalcy. Dr. Ian Chuang, who is currently the Chief Medical Officer at Elsevier shares his insights on how the healthcare ecosystem can prepare for the ‘new normal’ in a post-COVID-19 world. Edited excerpts;
Hithaishi C Bhaskar
“APAC, post-COVID-19, will see an explosion of innovation in digital health”

Dr Ian Chuang, Chief Medical Officer, EMEALAAP Health, Elsevier, Kansas City, Missouri Area, USA

How can healthcare ecosystems establish a strategic and resilient pandemic preparedness model?

There are and continue to be many lessons to be learned from this pandemic. Some of the areas are broad and systemic, requiring larger-scale evaluation of the fundamentals of the healthcare system and model of care itself. Ideally, we proceed with any change in a human-centered design thinking approach.

With many uncertainties about the disease, the COVID-19 pandemic has highlighted the importance of accessible and trusted data for frontline clinicians providing care. The pandemic crisis has sped up the delivery and accentuated the weakness in the healthcare system. The healthcare system was not ready when the disease first broke, putting a strain on the entire health system. As healthcare workers were over-taxed and reacting to the evolving crisis, patients were left to figure things out on their own. There was no recipe to fall back. Doctors’ offices were closed, elective surgeries canceled, and patients did not know where to seek care, let alone whether the Emergency Department was safe. The healthcare system was barely keeping up with the demands of COVID-19 related care; definitely, there was a shortfall of how well other care needs were met.

This story is from the August 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

This story is from the August 2020 edition of BioSpectrum Asia.

Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.

MORE STORIES FROM BIOSPECTRUM ASIAView All
Korea designs sweat resistant wearable robot sensor
BioSpectrum Asia

Korea designs sweat resistant wearable robot sensor

New electromyography (EMG) sensor technology that allows the long-term stable control of wearable robots and is not affected by the wearer's sweat and dead skin has gained attention recently.

time-read
1 min  |
March 2024
Why Singapore is Deep Tech Innovation Frontrunner
BioSpectrum Asia

Why Singapore is Deep Tech Innovation Frontrunner

Move over Artificial Intelligence Al) and Machine Learning ML), there's a new technology on the block Deep Tech. This latest technology holds immense potential for the life sciences industry, and Singapore is leaving no stone unturned in becoming a deep tech hub. From strategic investments to collaborative initiatives and a supportive regulatory environment, read on to find out about the country's initiatives in becoming a deep tech superpower.

time-read
4 mins  |
March 2024
Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?
BioSpectrum Asia

Can Shorter Regimens Eliminate Drug-Resistant Tuberculosis?

The World Health Organization (WHO) has taken a significant stride in the battle against Tuberculosis (TB) by introducing shorter drug regimens, aiming to curb a disease that claims countless lives globally. This innovative approach addresses the urgent need for more efficient treatments, especially in regions where TB's toll is highest. With traditional therapies often posing risks to liver health, these shortened regimens offer hope, minimising such concerns while enhancing treatment adherence.

time-read
5 mins  |
March 2024
How pharma is finally researching issues that primarily affect women
BioSpectrum Asia

How pharma is finally researching issues that primarily affect women

Pharma is now concentrating on problems that impact women. Female participation will now directly contribute to cures for diseases that affect them, since more studies specifically targeted at women are planned.

time-read
8 mins  |
March 2024
Championing PAY PARITY
BioSpectrum Asia

Championing PAY PARITY

Despite women's significant strides and contributions in the healthcare field, they are paid less than men. Unfortunately, as is the case in most spheres, persistent pay disparities plague the life sciences sector. How big is the gender pay gap in the pharma industry? Are companies and the industry doing enough to address this issue? Let's find out.

time-read
6 mins  |
March 2024
ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES
BioSpectrum Asia

ENGENDERING INCLUSIVITY & DIVERSITY IN LIFE SCIENCES

Globally, women constitute 46 per cent of the workforce in the public sector, whereas in the private sector, they represent 33 per cent. The public sector maintains a higher representation of women as employees compared to the private sector as per data from the World Bank.

time-read
10+ mins  |
March 2024
US FDA approves first medication to treat severe frostbite
BioSpectrum Asia

US FDA approves first medication to treat severe frostbite

The US Food and Drug Administration (FDA) has approved Eicos Sciences Inc’s Aurlumyn (iloprost) injection to treat severe frostbite in adults to reduce the risk of finger or toe amputation.

time-read
1 min  |
March 2024
Japanese startup RevolKa to create highly functional proteins by using AI-driven platform
BioSpectrum Asia

Japanese startup RevolKa to create highly functional proteins by using AI-driven platform

RevolKa, a venture-backed biotech startup providing a gamechanging protein engineering technology platform, based in Japan, has signed a contract research agreement with Sekisui Chemical.

time-read
1 min  |
March 2024
Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development
BioSpectrum Asia

Taiwan's Anbogen secures $12.5M for advancing precision oncology drug development

Taiwan-based startup Anbogen Therapeutics, a clinical-stage biotechnology company specialising in groundbreaking cancer drug development, has announced the successful completion of its Series A funding round.

time-read
1 min  |
March 2024
Samsung Biologics & LegoChem Biosciences team up for ADC development
BioSpectrum Asia

Samsung Biologics & LegoChem Biosciences team up for ADC development

South Korea-based Samsung Biologics, a global contract development and manufacturing organisation (CDMO), has signed a partnership agreement with LegoChem Biosciences, a Korean biotech company pioneering the research and development of antibody-drug conjugate (ADC) programmes.

time-read
1 min  |
March 2024